Metabolism News and Research

Latest Metabolism News and Research

Researchers commence Phase 2 research study to test CERE-110 for AD

Researchers at Banner Sun Health Research Institute are about to start the first Phase 2 research study to test a gene transfer agent for Alzheimer's disease. AD is a degenerative and ultimately fatal disorder affecting as many as five million Americans and that number is expected to soar to more than 11 million by 2040.

7 Apr 2010

Study: 75% of men with diabetes will develop some degree of ED

Erectile dysfunction is one of the most prevalent diabetes-induced complications in men; current estimates suggest that as many as 75% of men with diabetes will develop some degree of ED, and in many cases diabetics develop more severe forms of ED that are less responsive to standard drugs.

7 Apr 2010

OICR invests $415,000 to develop radiolabelled insulin probe for early detection of breast cancer

Dr. Tom Hudson, President and Scientific Director of the Ontario Institute for Cancer Research today announced an investment of $415,000 towards the development of a radiolabelled insulin probe for the early detection of breast cancer.

6 Apr 2010

International experts recommend individualized treatment for type 2 diabetic patients

Patients with type 2 diabetes are generally treated similarly despite the fact that they may have underlying differences that could affect their therapeutic response.

6 Apr 2010

AllCells expands office, laboratory production space and staff

AllCells LLC, a leading supplier of primary cell types, today announced it has completed its expansion into 10,000 additional square feet of office and laboratory production space located in Emeryville, California.

5 Apr 2010

Individualized therapies for treating type 2 diabetes recommended

Chevy Chase, MD-Patients with type 2 diabetes are generally treated similarly despite the fact that they may have underlying differences that could affect their therapeutic response. Seeking to address this critical health issue, an international multidisciplinary group of experts just issued recommendations for individualized treatment in a consensus statement to be published in the April 2010 issue of the Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).

5 Apr 2010

Study: Reduced birth weight may lower risk of obesity later in life

According to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism, regular moderate-intensity aerobic exercise led to a modest reduction in offspring birth weight without restricting the development of maternal insulin resistance.

5 Apr 2010

New report assesses optimal future for REMS

Two years after the Food and Drug Administration Amendments Act of 2007 gave FDA new powers to require Risk Evaluation and Mitigation Strategies for higher risk drugs and biologics, a new report concludes that an optimal future for REMS is possible if the agency adopts a systems approach when designing REMS programs and takes advantage of new technologies -- from electronic medical records to genetic testing -- that are changing the way medicine is practiced.

5 Apr 2010

Young adults with hyperthyroidism face increase risk of stroke

Young adults with overactive thyroid face a 44 percent increased risk of stroke compared to those with normal thyroid function, according to a study reported in Stroke: Journal of the American Heart Association.

3 Apr 2010

Researchers identify soy peptides that inhibit fat accumulation and reduce inflammation

If you're serious about losing weight, check out recent studies done in Elvira de Mejia's University of Illinois laboratory. Her research provides insight into the way a certain type of soy protein inhibits fat accumulation and reduces inflammation.

2 Apr 2010

Study shows imaging technique useful for planning cardiac procedures

For a patient with heart failure, checking whether the heart could benefit from bypass surgery or a stent is critical to ensuring survival. One imaging technique, positron emission tomography (PET) with the imaging agent fluorodeoxyglucose (FDG), may provide doctors with the information they need to make more informed treatment decisions, according to research published in the April issue of The Journal of Nuclear Medicine (JNM).

2 Apr 2010

ChromaDex signs agreement for commercial development of pterostilbene from University of Mississippi and USDA

A natural products chemistry company has licensed the rights for a promising botanical compound from the University of Mississippi and the Agricultural Research Service, which is the principal intramural scientific research agency of the U.S. Department of Agriculture.

2 Apr 2010

New clues into genomic complexity of Mimivirus

A study published online today in the journal Genome Research offers surprising new clues into the genomic complexity of the giant Mimivirus, the largest known virus in the world. Previous studies have shown that unlike most viruses, the Mimivirus has more genes than many bacteria and performs functions that normally occur only in cellular organisms.

2 Apr 2010

Ricerca Biosciences, Life Science Partner announce business development agreement

Ricerca Biosciences, a preclinical contract research drug development company, is pleased to announce a business development agreement with Life Science Partner (LSP) Co., Ltd., of Tokyo, Japan. Ricerca offers a unique spectrum of services for the areas of agrochemical registration, environmental analysis and pre-investigational new drug (IND) biopharmaceutical registration.

1 Apr 2010

Metabolon awarded U.S. patents for metabolomics methods

Metabolon, Inc., the leader in global metabolism through biomarker discovery and analysis, announced today the grant of US Patent 7,682,783 and US Patent 7,682,784 entitled "Methods for Drug Discovery, Disease Treatment and Diagnosis Using Metabolomics". The USPTO awarded the patents to Metabolon on March 23, 2010. The issued claims in the new patents are for uses of metabolomics to identify diagnostic biomarkers for depression and schizophrenia by profiling classes of metabolites in a sample.

1 Apr 2010

Role of membrane cholesterol in late keratinocyte differentiation analyzed

In a recent study initiated by Beiersdorf AG, Florian Spörl and colleagues evaluated the use of Roche Applied Science's xCELLigence System as a viable system to monitor not only cholesterol extraction and repletion but also cholesterol reorganization in human keratinocytes in real time. The xCELLigence System offers a novel approach to non-invasive long-term observation of membrane cholesterol dynamics in primary human keratinocytes.

1 Apr 2010

Repros Therapeutics announces response to FDA critique on proposed Phase II Androxal study

Repros Therapeutics Inc. today announced that the Company is sending a reply to the FDA's Division of Metabolism and Endocrinology Products following the Company's receipt of FDA's comments on the proposed Phase II study of Androxal® (enclomiphene) in the treatment of Type II diabetes under Repros' open IND. On February 2, 2010 the Company announced that Repros received confirmation from the Agency that the new IND is effective.

1 Apr 2010

Breastfeeding benefits expanded to cover mothers: Risk of diabetes reduced

Research has found a new benefit that mothers can obtain by breast feeding – decreased risk of type 2 diabetes. Benefits of breastfeeding for the baby have been cited for a long time now. In spite of this knowledge according to The Australian Breastfeeding Association there is a definite gap in awareness regarding health benefits that this simple yet effective practice can offer.

1 Apr 2010

Orexigen Therapeutics announces submission of Contrave NDA for treatment of obesity

Orexigen® Therapeutics, Inc. announced that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Contrave® (naltrexone SR/bupropion SR), its investigational drug for the treatment of obesity. The NDA is based on a substantial body of evidence gathered through the Contrave Obesity Research (COR) clinical program, which included over 4,500 patients.

1 Apr 2010

High-fructose corn syrup makes rats fat: Princeton University study questioned

"HFCS makes rats fat? I can hardly believe that Princeton sent out a press release yesterday announcing the results of this rat study. The press release says: "Rats with access to high-fructose corn syrup gained significantly more weight than those with access to table sugar, even when their overall caloric intake was the same."

31 Mar 2010

Metabolism News and Research

Latest Metabolism News and Research

Researchers commence Phase 2 research study to test CERE-110 for AD

Study: 75% of men with diabetes will develop some degree of ED

OICR invests $415,000 to develop radiolabelled insulin probe for early detection of breast cancer

International experts recommend individualized treatment for type 2 diabetic patients

AllCells expands office, laboratory production space and staff

Individualized therapies for treating type 2 diabetes recommended

Study: Reduced birth weight may lower risk of obesity later in life

New report assesses optimal future for REMS

Young adults with hyperthyroidism face increase risk of stroke

Researchers identify soy peptides that inhibit fat accumulation and reduce inflammation

Study shows imaging technique useful for planning cardiac procedures

ChromaDex signs agreement for commercial development of pterostilbene from University of Mississippi and USDA

New clues into genomic complexity of Mimivirus

Ricerca Biosciences, Life Science Partner announce business development agreement

Metabolon awarded U.S. patents for metabolomics methods

Role of membrane cholesterol in late keratinocyte differentiation analyzed

Repros Therapeutics announces response to FDA critique on proposed Phase II Androxal study

Breastfeeding benefits expanded to cover mothers: Risk of diabetes reduced

Orexigen Therapeutics announces submission of Contrave NDA for treatment of obesity

High-fructose corn syrup makes rats fat: Princeton University study questioned

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey